Med-Chemist : "Quintessential Medicinal Chemistry"
Thursday, March 21, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
›
Gilead Sciences, Inc. (Nasdaq: GILD) announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating th...
Wednesday, March 20, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
›
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced dosing of the first ...
Saturday, March 16, 2019
FDA Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
›
Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced that the U.S. Food and Dr...
Friday, March 15, 2019
Researchers find clues that depression may speed brain aging
›
In continuation of my updates on depression and its causes Memory and thinking skills naturally slow with age but now scientists are pe...
Thursday, March 14, 2019
Statins Help the Heart, No Matter What Your Age
›
Cholesterol-lowering statins are already known to help cut heart risks for seniors and the middle-aged. Now, research confirms the me...
Wednesday, March 13, 2019
Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
›
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Let...
Tuesday, March 12, 2019
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
›
In continuation f my update on ALKS 5461 Alkermes plc (Nasdaq: ALKS) announced that it received a Complete Response Letter ...
Saturday, March 9, 2019
SK Life Science Announces FDA Acceptance of NDA Submission for Cenobamate, an Investigational Antiepileptic Drug
›
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative biopharmaceutical company focused on developing a...
Friday, March 8, 2019
Pain Therapeutics Announces Feedback from Recent Meeting With FDA on Remoxy
›
In continuation of my update on Remoxy ER (oxycodone) Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug developmen...
Thursday, March 7, 2019
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
›
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a...
Wednesday, March 6, 2019
Zogenix Submits New Drug Application to U.S. Food & Drug Administration for Fintepla for the Treatment of Dravet Syndrome
›
Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced it has completed it...
Tuesday, March 5, 2019
Latest anti-retroviral drug therapies offer powerful solution for HIV infection-associated frailty
›
In continuation of my update on anti-retroviral drug reatment of the HIV/AIDS epidemic has seen remarkable advancements with the ad...
FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
›
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Psychop...
Saturday, March 2, 2019
FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus
›
In continuation of my updates on fluticasone propionate & salmeterol Mylan N.V. (NASDAQ: MYL) announced the U.S....
Friday, March 1, 2019
FDA Approves Egaten (triclabendazole) for the Treatment of Fascioliasis, a Neglected Tropical Disease
›
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fasciolias...
‹
›
Home
View web version